分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Engineered Self-Activatable Polymeric Nanozymes Precisely Eradicate Tumor-Associated Intramacrophage Bacteria to Potentiate Immunotherapy Based on Cluster of Differentiation 47 Blockade

Yunjian Yu, Jialu Bai, Juntao Fan, Zhuoyan Cui, Yong Zhou, Jinhao Chen, Youtao Xin, Meihui Su, Mahmoud Elsabahy, Hui Gao

Journal:ACS Nano

IF:17.3

DOI:10.1021/acsnano.5c15423

PMID:41712924

Published:2026-02-19

research field:肿瘤学免疫治疗活性氧信号通路纳米医学微生物组与癌症巨噬细胞生物学

Abstract

Immunotherapy for colorectal cancer (CRC) remains clinically limited by a profoundly immunosuppressive tumor microenvironment. Fusobacterium nucleatum (Fn), which selectively colonizes CRC tumors, drives this immunosuppression by persisting within macrophages and driving their M2 polarization. Here, we engineered a self-activatable polymeric nanozyme comprising ferrocene-bearing glycopolymers with artesunate (AS) payloads to eliminate intramacrophage Fn reservoirs and reprogram the macrophage immune ecosystem. These nanozymes were specifically engulfed by M2-like Fn-infected macrophages via mannose receptor-mediated endocytosis and then activated by overexpressed intracellular hydrogen peroxide to release ferrous ion and AS, which synergistically amplified cytotoxic reactive oxygen species (ROS) generation through Fenton chemistry. Concurrently, AS induced macrophage autophagy, promoting nanozyme-bacteria colocalization in autophagolysosomes to enhance ROS-mediated Fn killing. Remarkably, intracellular Fn eradication not only reversed the immunosuppressive phenotype of infected macrophages but also triggered paracrine signaling that drove M1 repolarization of neighboring uninfected macrophages. In both xenograft and orthotopic CRC models harboring intracellular Fn, the nanozymes can efficiently eliminate intracellular Fn and systemically remodel the macrophage immune landscape, significantly boosting the therapeutic efficacy of anti-CD47 immunotherapy. This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

本文使用的Yeasen产品

购物车
客服
转染试用